



EUROPEAN ASSOCIATION FOR  
DIABETIC EYE COMPLICATIONS

# 34<sup>th</sup> EAsDEC Meeting

Milan (Italy)

30 May - 1 June 2024

**Programme**



## Thursday 30<sup>th</sup> May 2024

- 15.00 Registration
- 16.00-16.45 AbbVie Symposium  
**A multidisciplinary approach to DME: Beyond the clinical routine**  
*Moderators: Stela Vujosevic and Rafael Simò*  
**Personalized treatment for patients with diabetes from ophthalmologist's and diabetologist's point of view**  
*Stela Vujosevic, Javier Zarranz-Ventura, Maria Vadalà, Rafael Simò*  
*Panelists: Javier Zarranz-Ventura, Maria Vadalà, Rafael Simò, Stela Vujosevic*
-  Q & A Session  
*All panelists*
- 17.00-17.45 Roche Symposium  
**Faricimab: disease control in DME through dual pathway inhibition**  
*Moderator: Rosangela Lattanzio*  
*Speakers: Francesco Viola and Maria Cristina Parravano*
-  Q & A Session  
*All panelists*
- 18.00 Official opening of the 2024 EAsDEC conference by Stela Vujosevic and Tunde Peto
- Welcome cocktail and finger food at the Congress venue

## Friday 31<sup>st</sup> May 2024

- 08.15 Registration
- 08.45–09.00 Introduction and Welcome  
*Tunde Peto, EAsDEC President*  
*Stela Vujosevic, Local Organizer*  
Brief salutations:  
*Professor Paola Cornelia Maria Muti, Head of Department of Biomedical, Surgical and Dental Sciences, University of Milan*  
*Professor Aldo Gianni, President of the Faculty of Medicine, University of Milan*
- 09.00–10.00 **SESSION 1**  
**Imaging in early diabetes and in special populations**  
*Moderators: Rosangela Lattanzio and Tom Gardner*
- 09.00–09.05 Introduction
- 09.05–09.16 **Retinal changes in Optical Coherence Tomography Angiography findings in patients with type 2 diabetes mellitus**  
D. Risimic (Serbia)
- 09.16–09.27 **Metabolic and structural predictors of long-term functional changes evaluated by multifocal electroretinogram in type 1 diabetes mellitus**  
M. Parravano (Italy)
- 09.27–09.38 **Winner of the Anne Katrin Sjolie Best Abstract Prize**  
**Progression of diabetic retinopathy in women with type 1 diabetes during and after pregnancy - results from a nationwide cohort**  
J. Ezban Larrson (Denmark)

- 09.38-09.49 **Longitudinal assessment of structural and microvascular changes in a pediatric population with type 1 diabetes mellitus**  
M.S. Polito (Italy)
- 09.49-10.00 **Development of an automated algorithm for grading of diabetic maculopathy according ESASO classification**  
M. Vadalà (Italy)
- 10.00-11.00 **SESSION 2**  
**Basic science**  
*Moderators: Rafael Simó and Reinier O. Schlingemann*
- 10.00-10.10 **EAsDEC Skills Award 2023 winner: Evaluation of sitagliptin eyedrops in TRPV2+/- rats, a non-diabetic model with diabetic retinopathy-like lesions**  
H. Ramos (Spain)
- 10.10-10.20 **Uncovering potential novel biomarkers for early diagnosis of diabetic retinopathy based on texture analysis of OCT-derived retinal images: evidence from an animal model of diabetes**  
A.F. Ambrosio (Portugal)
- 10.20-10.30 **Synergy between glyco-immuno-drugs and metal-organic framework-based nanoplatfoms: A novel therapeutic tool for diabetic retinopathy (ImmunoGlyMOFs)**  
F. Martín-Loro (Spain)
- 10.30-10.40 **The impact of misalignment with the external light cycle on diabetic retinopathy**  
E. Beli (United Kingdom)
- 10.40-10.50 **Elucidating the role of pentraxin 3 in diabetic retinopathy**  
R. Medina (United Kingdom)

- 10.50-11.00 **Ndr2 Kinase regulates microglial cells in diabetic retinopathy**  
H. Léger (Portugal)
- 11.00-11.10 **Association of reperfusion increase with runcaciguat in diabetic retinopathy models**  
Baschiera (Switzerland), E. J. Duh, C. Terjung, P. Sandner, K. Riecke, N. Bressler
- 11.10-11.40 Coffee & tea break
- 11.40-13.00 **SESSION 3**  
**Biomarker mediated decision - personalised approach**  
*Moderators: Francesco Bandello, Jakob Grauslund and Vincenza Bonfiglio*
- 11.40-11.42 Introduction to the session
- 11.42-11.53 **Aqueous humor proteome associated with incomplete anti-VEGF response in diabetic macular oedema**  
L. J. Cehofski (Denmark)
- 11.53-12.04 **Efficacy and safety of Faricimab in ALTIMETER: A trial exploring biomarkers of Ang-2 Inhibition in patients With DME**  
S. Vujosevic (Italy)
- 12.04-12.15 **Correlation between retinal regions and vitreous from donors with NPDR demonstrate promises in understanding diabetic retinal disease pathophysiology**  
P. Fort (USA)
- 12.15-12.26 **Characterization of retinal capillary nonperfusion in advanced stages of NPDR**  
I. Marques (Portugal)

- 12.26-12.37 **Identification of intraretinal microvascular abnormalities in eyes with advanced stages of NPDR: comparison between ultra-widefield FA, CFP and OCTA**  
A.C. Almeida (Portugal)
- 12.37-12.48 **Perspective for a conversion model of OCTA metrics in different stages of diabetic retinopathy: Angiovue vs Angioplex**  
A.R. Santos (Portugal)
- 12.48-13.00 **Rediscovering the clinical role of retinal microaneurysms in diabetic retinopathy: A quantitative multimodal retinal imaging approach**  
A. Arrigo (Italy)
- 13.00 Lunch (poster presenters first)
- 13.00-14.55 **SESSION 4**  
**Poster Session (see details below the ORAL Sessions)**
- 14.55-15.55 **Symposium**  
**Diabetic Retinopathy: The Diabetologists' view**  
*Moderators: Livio Luzi and Riccardo Candido*
- 14.55-15.10 **Why should the diabetologists be aware of the retinal status of their patients?**  
R. Simó (Spain)
- 15.10-15.20 **Diabetic retinopathy as an independent marker of cardiovascular disease in type 1 diabetes: results from a 5-year nationwide, longitudinal, matched case-cohort study**  
J. Grauslund (Denmark)
- 15.20-15.30 **Deep learning of retinal imaging to predict cardiovascular risk in patients with diabetes**  
O. Simó-Servat (Spain)

- 15.30-15.40 **Translational research in diabetes care**  
G. Zerbini (Italy)
- 15.40-15.55 **Metabolic control and diabetic retinopathy**  
R. Candido (Italy)
- 15.55-16.00 Moderators' summary of the session
- 16.00-16.20 **Update on diabetic retinopathy treatment**  
F. Bandello (Italy)
- 16.20-16.50 **Eva Kohner Lecture: Diabetic eye care: learning from the past and looking into the future**  
Professor Tunde Peto, Queen's University Belfast, United Kingdom  
Introduced by: Stela Vujosevic
- 16.50 **ANNUAL GENERAL MEETING**
- 19.00 Conference Dinner



## Saturday 1<sup>st</sup> June 2024

- 08.30 Registration
- 09.00-10.00 **SESSION 5**  
**Artificial intelligence and the power of big data**  
*Moderators: Stela Vujosevic and Reinier O. Schlingemann*
- 09.00-09.05 Introduction
- 09.05-09.16 **Assessing diabetic retinopathy staging with AI: a comparative analysis between pseudocolour and LED Imaging**  
M.V. Cicinelli (Italy)
- 09.16-09.27 **Real-life application of automated diabetic retinopathy classification with Retmarker Screening for R1/RO discrimination**  
P. Pereira (Portugal)
- 09.27-09.38 **Diabetic retinopathy screening with Artificial Intelligence: A pivotal experience in Italian Healthcare System**  
A. Piatti (Italy)
- 09.38-09.49 **Evaluating the digital surveillance programme for non-clinically significant maculopathy within Diabetic RetinaScreen**  
I. Brennan (Ireland)
- 09.49-10.00 **Diabetic eye screening in the population of patients over the age of 90 years**  
T. Peto (United Kingdom)
- 10.00-10.30 **The Mary Tyler Moore Vision Initiative; a catalyst for International Collaboration on Diabetic Retinal Disease**  
T. Gardner (USA)
- 10.30-10.55 Coffee & tea break

- 10.55-12.05 **SESSION 6**  
**New insights into DR evaluation and management**  
*Moderators: Flavia Chiosi and Francesco Viola*
- 10.55-10.58 Introduction by the moderators
- 10.58-11.09 **Structure-function correlation in different grades of disorganization of retinal layers in diabetic retinopathy**  
C. Alovisi (Italy)
- 11.09-11.20 **Week 48 Outcomes in Aflibercept 8 mg- and 2 mg-Treated patients by Prior DME Treatment Status: A subgroup Analysis of the Phase 2/3 PHOTON Trial**  
R. Lattanzio (Italy)
- 11.20-11.31 **National Institute for Health and Care Excellence (NICE) guideline for diabetic retinopathy management and monitoring**  
P. Burgess (United Kingdom)
- 11.31-11.42 **Management of vitreous hemorrhage in proliferative diabetic retinopathy**  
M.C. Savastano and C. Rizzo (Italy)
- 11.42-11.53 **Comparison of five diabetic retinopathy (DR) grading systems to support real world data (RWD) studies**  
N. Shah (United Kingdom)
- 11.53-12.05 **Non-uniform spatial distribution of macular lesions in type 2 diabetes mellitus**  
S. Aldington (United Kingdom)
- 12.05-12. 30 **The value of systematic reviews in diabetic eye disease**  
G. Virgili (Italy)
- 12.30-12.50 **Best Poster Prize Ceremony**  
*Moderators: Tunde Peto and Stela Vujosevic*
- 12.50-13.00 Closing Remarks

## IMAGING and AI

*Moderators: M.V. Cicinelli (Italy) and A.R. Santos (Portugal)*

- P01** Suspended scattering particles in motion (SSPiM) in diabetes mellitus  
A. Coletto (Italy)
- P20** Comparing AI-based EyeArt® and ophthalmologist assessment of diabetic retinopathy in minority women: a pilot study of the first use of AI in Oslo, Norway  
M. Karabeg (Norway)
- P24** Identification of active proliferative diabetic retinopathy: a preliminary test of a deep-learning model  
S. Dinesen (Denmark)
- P31** Reliability of UWF color fundus photography in diabetic retinal neovascularization identification compared to UWF fluorescein angiography  
R. Mahmoud (Egypt)
- P36** Ocular surface in patients with type 2 diabetes mellitus  
T. Zhmud (Ukraine)
- P37** Microvascular changes in eyes with non-proliferative diabetic retinopathy with or without macular microaneurysms: an OCT-angiography study  
C. Toma (Italy)
- P45** Analysis of the corneal sub-epithelial nerve plexus in patients with diabetes, with or without diabetic retinopathy  
D. Musetti (Italy)
- P47** Retinal Hyperreflective Foci (HF) and their automatic detection on Optical Coherence Tomography (OCT) through artificial intelligence (AI)  
C. Limoli (Italy)
- P53** OCT and OCT-A assessment of peripapillary changes and systemic correlations in type 1 diabetes mellitus  
G. Li Calzi (Italy)

- P61** Effects of diabetic retinopathy on anatomical and functional changes in eyes with AMD associated type 1 macular neovascularization after one year of treatment  
*L. Landini (Italy)*
- P69** Spatial disparities in hemorrhage distribution: Exploring variations between 10mm on UWF and 7 ETDRS fields in diabetic retinopathy using ultra widefield color fundus photos  
*S. Caboni (Italy)*
- P75** Optical coherence tomography analysis of children with type 1 diabetes mellitus  
*J. Vasiljević (Serbia)*
- P80** Interplay between ocular imaging and systemic markers: Unraveling correlations between OCT/OCT-A and biochemical parameters in type 1 diabetes patients  
*L.M. Brotto (Italy)*

## SCREENING

*Moderators: S. Aldington (United Kingdom) and O. Simò Servat (Spain)*

- P16** Using Artificial Intelligence in Diabetic Eye Screening Programmes: Perspectives from people with diabetes and screening staff in Northern Ireland, UK  
*L.N. Cushley (United Kingdom)*
- P25** Preliminary results from a new eye-screening service in Dodoma, Tanzania  
*C. Jamison (United Kingdom)*
- P39** Barriers and adherence to diabetic retinopathy screening services among children and young adults in Bangladesh  
*K. Curran (United Kingdom)*
- P60** Analysis of first screening visits for pregnant patients in the inaugural year of their integration within the Irish Diabetic Retina Screening (DRS) Programme  
*C. Rizzo (Ireland)*

- P72** Screening for diabetes related retinopathy in Bermuda – an observational study with the Bermuda Diabetes Centre  
[R. Thomas \(United Kingdom\)](#)
- P74** Ophthalmologists' perception and acceptance level for Artificial Intelligence use with Deep Learning Models, for Diabetic Retinal Screening in Ireland: A path forward  
[F. Ibrahim \(Ireland\)](#)
- P73** Community based Digital Surveillance screening of patients with stable proliferative diabetic retinopathy in the Irish Diabetic Retinopathy Screening Programme  
[S. Kelly \(Ireland\)](#)

## BASIC SCIENCE

*Moderators: A. Ferrulli (Italy) and F. Martìn-Loro (Spain)*

- P15** Sitagliptin prevents neurodegeneration in an experimental model of glaucoma induced by intravitreal administration of dexamethasone  
[P. Bogdanov \(Spain\)](#)
- P21** Systemic administration of M9 delays the progression of diabetic retinopathy in the animal model of type 1 diabetes mellitus: specific M2-induction of microglial cells  
[F. Cano-Cano \(Spain\)](#)
- P50** Preliminary results of the RETINAL study: effect of SARS-CoV-2 infection on retinal structure in patients with diabetes mellitus  
[M. Campanile \(Italy\)](#)
- P79** Development of predictive models for experimental diabetic retinopathy  
[Y. Sirman \(Ukraine\)](#)

## CLINICAL

*Moderators: M. Vadalà (Italy) and I. Marques (Portugal)*

- P07** Winner of the EAsDEC Skills Award - Clinical features related to optical coherence tomography angiography artifacts in patients with diabetic macular oedema  
*S. Tamer Kaderli (Turkey)*
- P08** Comparing a 60-degree Scanning Confocal Ophthalmoscope (SCO) device using staged mydriasis with the standard mydriatic digital cameras used in the NHS Diabetic Eye Screening Programme (DESP)  
*U. Javed (United Kingdom)*
- P10** OCT angiography analysis of retinal microvascular network in patients with diabetes mellitus: gender-based differences  
*G. Piccoli (Italy)*
- P23** Objective assessment of the dynamics of retinal nonperfusion zones in pregnant women with progression of diabetic retinopathy  
*N. Pomytkina (Russia)*
- P30** Retinal OCT biomarkers associated with reading performance in patients with persistent vs. resolved diabetic macular oedema  
*F. Ricardi (Italy)*
- P34** Inter-eye microvascular differences in patients with same-stage diabetic retinopathy revealed by OCTA  
*H. Stino (Austria)*
- P41** Endophthalmitis after intravitreal vascular endothelial growth factor injection for diabetic macular oedema and diabetic retinopathy  
*B.S. Thinggaard (Denmark)*
- P43** A correlation analysis between retrobulbar hemodynamics and treatment patterns in diabetic macular oedema eyes receiving intravitreal Faricimab  
*F. Chiosi (Italy)*
- P71** Diabetic retinopathy and low vision  
*A. D'Ambrosio (Italy)*

## IMAGING and TREATMENT

*Moderators: M. Parravano (Italy) and J. Grauslund (Denmark)*

- P19** Adjuvant dexamethasone in cataract surgery with treatment-requiring diabetic macular oedema  
G. George (United Kingdom)
- P29** Real-world treatment patterns and visual outcomes in the first 12 months of faricimab use in DME: UK FARWIDE-DME study  
C. Kiire (United Kingdom)
- P33** Early real-life experience with brolocizumab for diabetic macular oedema in a tertiary referral centre  
A. Gaggino (Italy)
- P54** Initial clinical experience with Faricimab in Diabetic Macular Oedema in an Italian tertiary centre  
S. Ginelli (Italy)
- P65** Anatomical and functional effects of an oral supplementation of Bromelain and Curcugreen in patients with focal Diabetic Macular Oedema  
L. Bifezzi (Italy)
- P83** To explore the effect of faricimab on clinic capacity in the treatment of diabetic macular oedema (DMO)  
J. Patel (United Kingdom)
- P85** The impact of Diabetic Retinopathy on the choriocapillaris in neovascular AMD  
M.G. Pignataro (Italy)
- P18** A method for removing the internal limiting membrane in vitreomacular traction syndrome in patients with proliferative diabetic retinopathy  
D. Lipatov (Russia)

## EPIDEMIOLOGY and SYSTEMIC

*Moderators: P. Burgess (United Kingdom) and  
C. Hernandez Pascual (Spain)*

- P17** Vision Loss due to Diabetes in Liverpool: correlation with deprivation and mortality  
*J. Nash (United Kingdom)*
- P35** Higher degree of diabetic macular oedema in regions with lower socioeconomic status  
*N. Mausavi (Denmark)*
- P55** Winner of the EAsDEC Skills Award - The role of general practitioners training in the increasing awareness on diabetes and its complications in children and adolescents  
*L. Tsutskiridze (Georgia)*
- P82** Epidemiology of diabetic retinopathy in Orhei region of Moldova  
*N. Palarie (Moldova)*
- P64** GLP-1 receptor agonist therapy in elderly men patients with type 2 diabetes mellitus and retinopathy  
*P. Senesi (Italy)*
- P27** Retinal microvascular fractal dimension and expression of miR-101 and miR-146a in type 2 diabetes mellitus and associated comorbidities  
*N. Popovic (Montenegro)*



## EAsDEC BOARD MEMBERS

Tunde Peto	<i>President</i>
Rafael Simo	<i>Past President</i>
Reinier Schlingemann	<i>Treasurer</i>
Stela Vujosevic	<i>Secretary</i>

## ORGANIZING SECRETARIAT



AIM Group International - Milan Office  
Viale Enrico Forlanini, 23  
20134 Milan, Italy  
Ph. +39 02 566011  
[easdec2024@aimgroup.eu](mailto:easdec2024@aimgroup.eu)

## REGISTRATION DESK OPENING HOURS

The Organizing Secretariat desk will be open according to the following schedule:

Thursday May 30 <sup>th</sup> 15.00 - 18.00	Friday May 31 <sup>th</sup> 08.15 - 17.00	Saturday June 1 <sup>st</sup> 08.30 - 13.00
--	--	--

## EXHIBITION

An onsite exhibition of pharmaceutical and technical products will take place in the Congress venue.

## LANGUAGE

The official language of the congress is English. Simultaneous translation will not be provided.




## ACCESS TO THE CONGRESS

Participants are kindly required to wear their own badge during all Congress activities.

The badge gives access to the scientific sessions, exhibition area, coffee breaks and lunch.

The badge gives access to the scientific sessions, exhibition area, coffee breaks and lunch.

*Which colour is your badge?*

Participants  Exhibitors  Faculty 

## COFFEE BREAKS AND LUNCH

Coffee stations and lunch will be offered in the courtyard of the Congress venue as follows:

31 May 2024: Coffee & tea break from 11.00 to 11.30

Light Lunch from 13.00 to 14.55

1 June 2024: Coffee & tea break from 10.30 to 10.55

## OFFICIAL OPENING

On May 30, 2024, a Welcome Cocktail and Finger Food will be served from 18.00, right after the Official Opening held by Stela Vujosevic and Tunde Peto.

## CUSTOMER SATISFACTION SURVEY & CERTIFICATE OF ATTENDANCE

At the end of the event, participants will receive the customer satisfaction survey by e-mail. The certificate of attendance will be available after completing it. Your feedback will help improve our future activities.

## WI-FI

Wi-Fi credentials are displayed in the Congress area.

## CLOAKROOM

Cloakroom and luggage storage facility is available in the Congress area.

## INSURANCE

Congress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the congress.

## PRIVACY POLICY

The information on the processing of personal data pursuant to European Regulation No. 679 of 2016 is published on the event's website at the following address:

[www.easdec.org](http://www.easdec.org)

Please visit the website for any further information.

## MOBILE PHONES

Delegates are kindly required to set their mobile phones on silent mode in areas where scientific sessions are ongoing.

## NO-SMOKING

Smoking in the congress area is forbidden.

## REGISTRATION FEES

## ONSITE

22% VAT included

Late Standard	280 €
Late Resident*	200 €
Conference Dinner for registered Delegates	20 €
Welcome Event + Conference dinner (for accompanying persons only)	50 €

### *The Standard and Resident registration fees include:*

- Access to all sessions and exhibition area
- Refreshments during the conference
- Welcome cocktail at the Congress venue

### *The accompanying person registration fee includes:*

- Welcome cocktail at the Congress venue
- Conference dinner

## PAYMENT

Credit Card: All major credit cards are accepted (American Express, VISA, Eurocard/Master Card)

Cash: Payments will be accepted in EURO only.

## CONFERENCE DINNER

Participants who have purchased the ticket for the Congress Dinner will receive a coupon at the Registration Desk during the check-in. The Dinner will be held at Istituto dei Ciechi, Via Vivaio 7 - 20122 Milan from 19.00.



*Fondazione-Onlus Istituto dei Ciechi (Foundation for Blind People) in Milan is a valuable institution for hospitality, education and vocational training for blind, visually impaired and visually multi-disabled people. This is the reason why the Paolina Brugnatelli Foundation, born in Milan in 2010 as a non-profit organization, has chosen the Istituto dei Ciechi for the Art 4.0 Project, giving blind people the opportunity to “touch the art” thanks to the advanced tactile digital technology XR Connector and virtual reality.*

*This project recreates the first tactile experience in Italy, using a pair of haptic gloves capable of providing a “tangible glimpse” of the world's most beautiful sculptural artworks to those who lack the opportunity in real life.*

*Through the Art 4.0 Project, The Paolina Brugnatelli Foundation is pioneering the first Italian Virtual Museum at Fondazione-Onlus Istituto dei Ciechi, which is the most prestigious venue for such an initiative.*

### **INFORMATION FOR PRESENTERS**

Presentations must be prepared in Microsoft PowerPoint and saved on a USB drive.

It is recommended to have authorization for any picture in the presentations and to disclose the source.

Speakers are required to deliver their presentations to the Slide Centre at least one hour before the beginning of your session.

It is not allowed to use personal laptops for any presentation.

Speakers are required to reach the Plenary Room at least 15 minutes before the beginning of their session, respecting the timing allowed to the session and each presentation.

All presentations, discussions and questions must be in English.

### **POSTER EXHIBITION**

Posters must be printed in A0 international format (841x1189mm) with a vertical orientation.

Poster setup time is scheduled for 30<sup>th</sup> May, from 15.00 and must remain hung on the panel board to let participants view them at their convenience.

Posters must be fixed to the panel board with the corresponding number, as indicated in the scientific programme.

**The presenter of each poster is called to remain close to the poster station during the Session 4, on Friday 31<sup>st</sup> May, from 13.00 to 14.55**

Poster dismantling is scheduled on 1<sup>st</sup> of June from 13.00.

The Organizer are not responsible for loss of any posters that have not been removed by the end of the event.











---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

## Notes



# 34<sup>th</sup> EAsDEC Meeting

We are grateful to all organizations who have generously supported the 34<sup>th</sup> EAsDEC Meeting

## SILVER SPONSORS

abbvie



## BRONZE SPONSORS



icare®



## SUPPORTERS

